Last updated: March 9, 2026
What is the drug identified by NDC 00955-1006?
NDC 00955-1006 refers to Rituximab (brand name Rituxan). It is a monoclonal antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
What is the current market landscape?
Market Size and Key Players
The Rituximab market was valued at approximately $3.8 billion in 2022. Growth drivers include expanding indications, biosimilar entries, and increasing adoption in autoimmune diseases.
Major competitors include:
- Roche (original manufacturer)
- Biosimilar versions from Samsung (Truxima), Celltrion (Riabni), and Pfizer (Ruxience).
Market Trends
- Biosimilar penetration: Biosimilars accounted for approximately 25% of Rituximab sales in 2022. Entry of biosimilars in 2019 boosted competition and reduced prices.
- Indication expansion: FDA approvals for additional autoimmune conditions extend market opportunity.
- Pricing dynamics: Original products ranged from $4,500 to $6,000 per infusion; biosimilars are generally priced 20-30% lower.
Regulatory Status
- Original Rituxan approved in 1997.
- Biosimilars approved starting in 2018.
- Ongoing patent litigations and patent cliffs influence market share shifts.
What are the price projections?
Short-term (Next 2 Years)
- The average wholesale price (AWP) for Rituximab is currently $4,200–$4,800 per infusion.
- Biosimilar prices are expected to hover around $3,200–$3,600 per infusion due to competition.
- Price erosion of 10-15% in the biosimilar segment is expected as market penetration continues.
Long-term (3–5 Years)
- Biosimilar market share could reach 50-60%.
- Price levels for biosimilars may stabilize around $2,800–$3,200 per infusion.
- Original Rituxan prices could decline by 30-40% from current levels due to biosimilar competition and payer pressure.
Volume vs. Price
- Volume growth is driven by increasing indications and chronic use.
- Price reductions are offset by increased utilization; net revenue may stabilize or slightly decline.
Assumptions
- Biosimilar market share increases steadily, reaching 50-60% by 2026.
- Regulatory policies continue to favor biosimilar adoption.
- Payer negotiations favor lower prices over time.
Comparative Price Data
| Year |
Price per infusion (Biosimilar) |
Price per infusion (Original) |
Market Share Biosimilars |
| 2023 |
$3,400–$3,600 |
$4,500–$6,000 |
25% |
| 2025 |
$2,800–$3,200 |
$4,000–$5,200 |
50–60% |
How do regulatory trends impact pricing?
Health policies promoting biosimilar uptake and patent litigations influence pricing and market share. Countries adopting policies that encourage biosimilar use typically see sharper price declines.
What are the key risks to price stability?
- Patent litigation extending exclusivity.
- Market entry delays for biosimilars.
- Payer resistance to further price reductions.
- Regulatory hurdles reducing biosimilar availability or approval.
Summary of Key Data Points
- Market valuation: ~$3.8 billion (2022).
- Original product price: $4,500–$6,000 per infusion.
- Biosimilar prices: $3,200–$3,600 per infusion.
- Biosimilar market share (2023): 25%.
- Projected biosimilar market share (2026): 50–60%.
- Price decline forecast (2023–2026): 30–40% for original Rituximab.
Key Takeaways
- The Rituximab market is increasingly competitive due to biosimilar entry.
- Price erosion will continue, driven by biosimilar adoption.
- Revenue stability depends on volume growth and indications expansion.
- Regulatory and patent decisions heavily influence future pricing.
- The market remains sizable with lucrative potential in autoimmune diseases.
FAQs
-
What drives the growth of Rituximab's market?.
Indications expansion, biosimilar entry, and increased autoimmune disease prevalence.
-
How much are biosimilar Rituximabs priced compared to the original?.
They are priced 20-30% lower, generally around $3,200–$3,600 per infusion.
-
What is the expected market share of biosimilars by 2026?.
Between 50 and 60%.
-
Will the prices of original Rituximab decrease significantly?.
Yes, with estimates of a 30-40% decline over the next three years.
-
What risks could affect future prices?.
Patent disputes, regulatory hurdles, payer resistance, and slow biosimilar adoption.
References
[1] IQVIA. (2022). Oncology Market Report.
[2] FDA. (2022). Approved Biosimilars for Rheumatoid Arthritis.
[3] EvaluatePharma. (2022). Biosimilar Landscape.
[4] Medicare Payment Advisory Commission. (2022). Trends in Biologic Pricing.
[5] Harvard Business Review. (2021). Biosimilar Adoption and Market Dynamics.
